Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 4, 2014, Pages 624-634

  Chimenti, Isotta ^a   Gaetani, Roberto ^b   Forte, Elvira ^b   Angelini, Francesco ^b   De Falco, Elena ^a   Zoccai, Giuseppe Biondi ^a   Messina, Elisa ^b   Frati, Giacomo ^a,c   Giacomello, Alessandro ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Adult stem cells; Cardiac cell therapy; Cardiospheres; Good Manufacturing Practice compliance; Human sera

Indexed keywords

CULTURE MEDIUM; STEM CELL FACTOR RECEPTOR;

ANIMAL; BIOSYNTHESIS; BOVINE; CHEMISTRY; CULTURE MEDIUM; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; SERUM; STEM CELL;

ANIMALS; CATTLE; CELL CULTURE TECHNIQUES; CULTURE MEDIA; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; PROTO-ONCOGENE PROTEINS C-KIT; SERUM; STEM CELLS;

EID: 84897963100     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12210     Document Type: Article

References (55)

1. Gaetani R, Barile L, Forte E, et al. New perspectives to repair a broken heart. Cardiovasc Hematol Agents Med Chem. 2009; 7: 91-107.
2. Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011; 50: 258-65.
3. Malliaras K, Kreke M, Marban E. The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther. 2011; 90: 532-41.
4. Abdelwahid E, Siminiak T, Guarita-Souza LC, et al. Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications. Curr Cardiol Rev. 2011; 7: 201-12.
5. Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol. 2012; 59: 942-53.
6. Barile L, Messina E, Giacomello A, et al. Endogenous cardiac stem cells. Prog Cardiovasc Dis. 2007; 50: 31-48.
7. Malliaras K, Marban E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull. 2011; 98: 161-85.
8. Forte E, Chimenti I, Barile L, et al. Cardiac cell therapy: the next (re)generation. Stem Cell Rev. 2011; 7: 1018-30.
9. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379: 895-904.
10. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378: 1847-57.
11. Takehara N, Tsutsumi Y, Tateishi K, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008; 52: 1858-65.
12. Mannello F, Tonti GA. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!. Stem Cells. 2007; 25: 1603-9.
13. Heiskanen A, Satomaa T, Tiitinen S, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells. 2007; 25: 197-202.
14. Sundin M, Ringden O, Sundberg B, et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007; 92: 1208-15.
15. Tekkatte C, Gunasingh GP, Cherian KM, et al. "Humanized" stem cell culture techniques: the animal serum controversy. Stem Cells Int. 2011; 2011: 504723.
16. Ma HY, Yao L, Yu YQ, et al. An effective and safe supplement for stem cells expansion ex vivo: cord blood serum. Cell Transplant. 2012; 21: 857-69.
17. Kaupisch A, Kennedy L, Stelmanis V, et al. Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. J Cardiovasc Transl Res. 2012; 5: 605-17.
18. Naaijkens BA, Niessen HW, Prins HJ, et al. Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res. 2012; 348: 119-30.
19. Bieback K, Hecker A, Kocaömer A, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009; 27: 2331-41.
20. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95: 911-21.
21. Chimenti I, Gaetani R, Barile L, et al. Isolation and expansion of adult cardiac stem/progenitor cells in the form of cardiospheres from human cardiac biopsies and murine hearts. Methods Mol Biol. 2012; 879: 327-38.
22. Li TS, Cheng K, Lee ST, et al. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells. 2010; 28: 2088-98.
23. Chimenti I, Forte E, Angelini F, et al. From ontogenesis to regeneration: learning how to instruct adult cardiac progenitor cells. Prog Mol Biol Transl Sci. 2012; 111: 109-37.
24. Altomare C, Barile L, Marangoni S, et al. Caffeine-induced Ca(2 + ) signaling as an index of cardiac progenitor cells differentiation. Basic Res Cardiol. 2010; 105: 737-49.
25. Forte E, Miraldi F, Chimenti I, et al. TGFβ-dependent epithelial-to-mesenchymal transition is required to generate cardiospheres from human adult heart biopsies. Stem Cells Dev. 2012; 21: 3081-90.
26. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007; 115: 896-908.
27. Lee ST, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol. 2011; 57: 455-65.
28. Fabrizi C, Angelini F, Chimenti I, et al. Thrombin and thrombin-derived peptides promote proliferation of cardiac progenitor cells in the form of cardiospheres without affecting their differentiation potential. J Biol Regul Homeost Agents. 2011; 25: S43-51.
29. Barth AS, Zhang Y, Li TS, et al. Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Transl Med. 2012; 1: 289-97.
30. Tan SC, Carr CA, Yeoh KK, et al. Identification of valid housekeeping genes for quantitative RT-PCR analysis of cardiosphere-derived cells preconditioned under hypoxia or with prolyl-4-hydroxylase inhibitors. Mol Biol Rep. 2012; 39: 4857-67.
31. Dimmeler S, Zeiher AM. Cell therapy of acute myocardial infarction: open questions. Cardiology. 2009; 113: 155-60.
32. Haack-Sorensen M, Friis T, Bindslev L, et al. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. Scand J Clin Lab Invest. 2008; 68: 192-203.
33. Röth A, Schneider L, Himmelreich H, et al. Impact of culture conditions on the proliferative lifespan of human T cells in vitro. Cytotherapy. 2007; 9: 91-8.
34. Poloni A, Maurizi G, Serrani F, et al. Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate. Cell Prolif. 2012; 45: 66-75.
35. Wachs FP, Couillard-Despres S, Engelhardt M, et al. High efficacy of clonal growth and expansion of adult neural stem cells. Lab Invest. 2003; 83: 949-62.
36. Silva A, Pereira J, Oliveira CR, et al. BDNF and extracellular matrix regulate differentiation of mice neurosphere-derived cells into a GABAergic neuronal phenotype. J Neurosci Res. 2009; 87: 1986-96.
37. Wu Z, Falciatori I, Molyneux LA, et al. Spermatogonial culture medium: an effective and efficient nutrient mixture for culturing rat spermatogonial stem cells. Biol Reprod. 2009; 81: 77-86.
38. Merhi-Soussi F, Angénieux B, Canola K, et al. High yield of cells committed to the photoreceptor fate from expanded mouse retinal stem cells. Stem Cells. 2006; 24: 2060-70.
39. Gupta N, Henry RG, Strober J, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012; 4: 155ra37.
40. Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013; 11: 643-52.
41. Mendez I, Dagher A, Hong M, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg. 2000; 92: 863-9.
42. Choi J, Chung JH, Kwon GY, et al. Effectiveness of autologous serum as an alternative to fetal bovine serum in adipose-derived stem cell engineering. Cell Tissue Bank. 2012; 14: 413-22.
43. Aghayan HR, Arjmand B, Norouzi-Javidan A, et al. Clinical grade cultivation of human Schwann cell, by the using of human autologous serum instead of fetal bovine serum and without growth factors. Cell Tissue Bank. 2012; 13: 281-5.
44. De Falco E, Scafetta G, Napoletano C, et al. A standardized laboratory and surgical method for in vitro culture isolation and expansion of primary human Tenon's fibroblasts. Cell Tissue Bank. 2012; 14: 277-87.
45. Bieback K, Hecker A, Schlechter T, et al. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. Cytotherapy. 2012; 14: 570-83.
46. Kocaoemer A, Kern S, Klüter H, et al. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells. 2007; 25: 1270-8.
47. Ferro F, Spelat R, Beltrami AP, et al. Isolation and characterization of human dental pulp derived stem cells by using media containing low human serum percentage as clinical grade substitutes for bovine serum. PLoS ONE. 2012; 7: e48945.
48. Trombi L, Pacini S, Montali M, et al. Selective culture of mesodermal progenitor cells. Stem Cells Dev. 2009; 18: 1227-34.
49. Bieback K, Ha VA, Hecker A, et al. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A. 2010; 16: 3467-84.
50. Fekete N, Rojewski MT, Fürst D, et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS ONE. 2012; 7: e43255.
51. Rauch C, Feifel E, Amann EM, et al. Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX. 2011; 28: 305-16.
52. Felka T, Schäfer R, De Zwart P, et al. Animal serum-free expansion and differentiation of human mesenchymal stromal cells. Cytotherapy. 2010; 12: 143-53.
53. Riem Vis PW, Sluijter JP, Soekhradj-Soechit RS, et al. Sequential use of human-derived medium supplements favours cardiovascular tissue engineering. J Cell Mol Med. 2012; 16: 730-9.
54. Chimenti I, Rizzitelli G, Gaetani R, et al. Human cardiosphere-seeded gelatin and collagen scaffolds as cardiogenic engineered bioconstructs. Biomaterials. 2011; 32: 9271-81.
55. Gaetani R, Rizzitelli G, Chimenti I, et al. Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. J Cell Mol Med. 2010; 14: 1071-7.